比卡鲁胺联合戈舍瑞林治疗晚期前列腺癌患者的疗效观察

doi:10.3969/j.issn.1671-7171.2019.01.004

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】 To investigate the efficacy of bikalumide in patients with advanced prostate cancer.【Methods】 A total of 92 patients with advanced prostate cancer admitted in our hospital from January 2016 to December 2017 were randomly divided into two groups, with 46 cases in each group. Patients in the control group received routine therapy with foserelin, while patients in the observation group was treated with bikalumide on the basis of foserelin routine treatment. The clinical efficacy and serum prostate specific antigen (PSA), vascular endothelial growth factor (VEGF), miRNA-34a (miR-34a), insulin-like growth factor-1 (IGF-1) levels and SMYD3 positive expression rate were compared before and after treatment. Quality of life measurement scale (QLQ-C30) score and patient satisfaction were evaluated as well.【Results】 The total effective rate of the observation group was 95.65% (44/46), which was significantly higher than that of the control group (80.43% (37/46)). The difference was statistically significant (P<0.05). There were no statistically significant differences between the two groups in the levels of PSA, VEGF, miR-34a,IGF-1, SMYD3 and QLQ-C30 before treatment (P>0.05). After treatment, the levels of PSA, VEGF, IGF- and SMYD3 in the observation group were lower than those in the control group, and the level of miR-34a and QLQ-C30 score were higher than those in the control group (P<0.05). The patient satisfaction in the observation group was 95.65%, which was significantly higher than that in the control group 54.35%, and the difference was statistically significant (P<0.05). 【Conclusion】 Bikalumide combined with goserelin have significant therapeutic effect in patients with advanced prostate cancer, which can reduce levels of PSA VEGF and IGF-1, increase miR-34a level, effectively control SMYD3 expression, improve the quality of life and enhance patient satisfaction.

Key words： Prostatic Neoplasms/DT Drug Therapy Combination

Received: 25 December 2018

PACS:

R737.25

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2019.01.004 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2019/V36/I1/11

[1] 齐金蕾,王黎君,周脉耕,等.1990-2013年中国男性前列腺癌疾病负担分析[J].中华流行病学杂志,2016,37(6):778-782.
[2] 庞宽,周泽光,黄英凡,等.比卡鲁胺联合戈舍瑞林治疗晚期前列腺癌的临床疗效及安全性评价[J].中国临床药理学杂志,2016, 3 (1):224-226.
[3] 曲静坤.比卡鲁胺联合戈舍瑞林间歇性治疗局部晚期前列腺癌的临床评价[J].中国药业,2016,25(11):46-48.
[4] 李飞宇,王霄英,肖江喜,等.中国男性前列腺癌MRS体素诊断标准[J].中国医学影像技术,2009,25(5):833-836.
[5] 王岩,朱琳,陈鹏,等.肿瘤患者生命质量测定量表EORTC QLQ-C30维文版评价[J].中国卫生统计,2015,32(3):512-513.
[6] 张智勇,乔西民.血清PSA 及超声引导穿刺活检对前列腺癌病理分期预测价值研究[J].癌症进展,2017,15(9):1076-1078.
[7] 王楷峰.饮食因素、生活方式与前列腺癌发生发展的研究进展[J].国际泌尿系统杂志,2018,38(2):299-303.
[8] 吴强,桂亚平,吴登龙.DWI和ADC在诊断前列腺增生和前列腺癌中的应用[J].湖南师范大学学报(医学版),2018,15(3):176-179.
[9] 谢云峰,黄一鸣.醋酸戈舍瑞林缓释植入剂长期应用对前列腺癌患者去势后的临床疗效与安全性[J].中国临床药理学杂志,2017,33(14):1314-1316.
[10] 张晓冬,贺利民,马磊,等.戈舍瑞林联合比卡鲁胺间歇性与连续性治疗对晚期前列腺癌患者前列腺抗原及免疫功能的影响[J].现代肿瘤医学,2018,26(3):426-429.
[11] 王炜,李传刚,刘辉,等.前列腺特异性抗原对前列腺癌诊断价值的探讨[J].中国医科大学学报,2016,45(1):61-65.
[12] Su J, Aslim EJ, Aydin H,et al.A rare case of isolated castrate resistant bilateral testicular metastases in advanced prostate cancer[J].Asian J Urol,2018, 5(2):127-130.
[13] 洪善超,殷皓,王婷婷,等.微小RNA-320a在前列腺癌中的表达及其功能[J].中华实验外科杂志,2018,35(5):944-947.
[14] 吴晓华,许晋川,吕静美,等.创面负压引流联合重组人生长激素治疗老年糖尿病足的疗效观察[J].医学临床研究,2018,35(7):1298-1300.
[15] 夏传友,李路超,李孝峰,等.组蛋白甲基化酶SMYD3在前列腺癌组织的表达及对mTOR通路的影响[J].山东大学学报(医学版),2016,54(5):12-16.
[16] 郭钏,杨舸,蒲永昌,等.比卡鲁胺联合戈舍瑞林对晚期前列腺癌患者肿瘤组织中Raptor蛋白及SMYD3表达的影响[J].实用临床医药杂志,2017,21(15):53-56.